List of Excipients in Branded Drug COREG

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	COREG	carvedilol phosphate	0007-3370	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	COREG	carvedilol phosphate	0007-3370	CROSPOVIDONE
GlaxoSmithKline LLC	COREG	carvedilol phosphate	0007-3370	HYDROGENATED CASTOR OIL
GlaxoSmithKline LLC	COREG	carvedilol phosphate	0007-3370	MAGNESIUM STEARATE

COREG Excipient Strategy and Commercial Opportunities in Carvedilol Formulations

Last updated: October 13, 2026

COREG is the branded immediate-release carvedilol tablet marketed by GlaxoSmithKline, while COREG CR is an extended-release carvedilol phosphate capsule. The immediate-release product has a low-complexity excipient system and limited current patent protection. The larger commercial opportunity is in generic supply, excipient optimization, modified-release delivery, fixed-dose combinations, and lifecycle products that improve adherence or reduce formulation cost.

What is COREG and which formulations use carvedilol?

COREG contains carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic blocking activity. The FDA approved COREG tablets for heart failure and left ventricular dysfunction following myocardial infarction. COREG CR uses a once-daily extended-release formulation for hypertension and heart failure-related indications. [1,2]

Product	Active ingredient	Dosage form	Typical dosing concept	Primary formulation opportunity
COREG	Carvedilol	Immediate-release tablet	Usually twice daily	Low-cost generic manufacturing and excipient substitution
COREG CR	Carvedilol phosphate	Extended-release multiparticulate capsule	Once daily	Release-control technology, capsule filling, bead-coating efficiency
Generic carvedilol	Carvedilol	Immediate-release tablet	Usually twice daily	API and excipient cost reduction
Generic carvedilol phosphate ER	Carvedilol phosphate	Extended-release capsule	Once daily	Bioequivalence, coating process, and supply-chain competition

COREG is commercially distinct from COREG CR. The tablet relies on conventional disintegration and dissolution. COREG CR uses controlled-release particles contained within a capsule, creating more demanding manufacturing and bioequivalence requirements.

What excipients are used in COREG tablets?

The COREG tablet platform uses conventional oral solid-dose excipients. FDA labeling identifies excipient classes including lactose monohydrate, crospovidone, povidone, hypromellose, colloidal silicon dioxide, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, and colorants that vary by strength. [1]

Functional role of the COREG tablet excipients

Excipient	Primary function	Commercial relevance
Lactose monohydrate	Diluent and tablet bulk	Low-cost, widely available; potential supply-chain substitution
Crospovidone	Superdisintegrant	Supports rapid tablet breakup and dissolution
Povidone	Binder	Controls granule strength and tablet integrity
Hypromellose	Film-forming polymer	Supports coating and appearance
Colloidal silicon dioxide	Glidant	Improves powder flow and blend uniformity
Magnesium stearate	Lubricant	Reduces compression and ejection friction
Polyethylene glycol	Plasticizer or coating aid	Supports film flexibility
Sucrose	Coating component	Contributes to tablet appearance and swallowability
Titanium dioxide	Opacifier and colorant	Used in film-coating systems
Iron oxides	Colorants	Distinguish dosage strengths

The formulation does not require a specialized release-control polymer. That limits the defensibility of an excipient-based product strategy but improves the commercial position of manufacturers that can optimize raw-material cost, compression yield, coating time, and tablet appearance.

What excipient strategy supports a generic COREG tablet?

A generic COREG tablet can generally use a different qualitative and quantitative excipient composition if it meets the applicable quality, performance, and bioequivalence requirements. The central technical targets are dissolution similarity, tablet robustness, content uniformity, stability, and consistent disintegration.

High-value formulation levers

Lactose and filler selection

Lactose is a major cost and processing variable. An applicant can evaluate anhydrous lactose, spray-dried lactose, microcrystalline cellulose, dibasic calcium phosphate, or co-processed filler systems. The choice affects:

• Powder flow
• Compactability
• Tablet hardness
• Disintegration
• Moisture sensitivity
• Milling and blending requirements

A switch from lactose to microcrystalline cellulose may improve compactability but can alter disintegration and dissolution. Dibasic calcium phosphate may improve flow and reduce moisture uptake but can produce a harder, slower-disintegrating tablet.

Superdisintegrant optimization

Crospovidone is well suited to rapid disintegration. Alternatives include croscarmellose sodium and sodium starch glycolate. The commercial objective is not simply to reproduce the reference formulation. It is to achieve the same release profile with lower material cost, improved robustness, or better compatibility with the selected filler and lubricant.

Lubrication control

Magnesium stearate concentration and blending time can materially affect dissolution. Over-lubrication can create hydrophobic particle surfaces and slow tablet breakup. A controlled lubrication process is therefore important for a high-volume carvedilol product, particularly when direct compression is used.

Film coating

The color-coded strength system creates an opportunity for coating-process optimization. A manufacturer can reduce coating weight, use a premixed coating system, or replace part of the sucrose and polymer system with a conventional aqueous film coat. The product must preserve strength differentiation, identification, stability, and appearance.

What excipients are used in COREG CR?

COREG CR uses a multiparticulate extended-release system. The capsule contains drug-loaded particles or beads that release carvedilol over an extended period. FDA labeling identifies materials including sugar spheres, hypromellose, povidone, ethylcellulose, talc, triethyl citrate, gelatin, titanium dioxide, and iron oxides. [2]

Why COREG CR is more difficult to copy

The commercial and technical barrier is the release-control architecture rather than the capsule shell. Key variables include:

• Drug loading onto starter spheres
• Uniformity of the drug-containing layer
• Polymer coating thickness
• Ethylcellulose permeability
• Plasticizer distribution
• Particle-size distribution
• Capsule fill-weight control
• Dose dumping resistance
• Food-effect performance

Ethylcellulose is the main release-controlling polymer in the disclosed system. Hypromellose and povidone can support the drug-layer structure, while triethyl citrate improves polymer-film flexibility. Talc can function as an anti-tacking or processing aid.

A generic applicant may use a different polymer architecture, but the alternative must produce comparable in vitro and in vivo release. This increases development cost and makes manufacturing scale-up more material than for the immediate-release tablet.

What commercial opportunities exist for COREG excipients?

The largest opportunities are in excipient supply, formulation services, and product development rather than in proprietary excipient ownership.

1. Generic carvedilol tablet manufacturing

Generic carvedilol tablets have a mature regulatory pathway and a broad supplier base. Excipient companies can compete through:

• Direct-compression premixes
• Low-dust powder systems
• High-flow lactose grades
• Co-processed fillers
• Ready-to-use film-coating systems
• Lubricant and glidant optimization
• Stability packages for humid climates

Because carvedilol is a high-volume cardiovascular drug, small reductions in tablet weight, coating time, rejection rate, or raw-material cost can produce meaningful annual savings.

2. Extended-release multiparticulate platforms

COREG CR provides a platform opportunity for contract development and manufacturing organizations with expertise in:

• Fluid-bed coating
• Drug layering
• Ethylcellulose membrane control
• Multiparticulate blending
• Capsule filling
• In vitro-in vivo correlation
• Food-effect studies

The commercial proposition is stronger for a complete formulation platform than for a single excipient. Polymer suppliers can support development through coating-grade ethylcellulose, hypromellose, plasticizers, anti-tacking agents, and process-development services.

3. Once-daily adherence products

COREG CR was developed partly to reduce dosing frequency. A new once-daily carvedilol product could compete through:

• Lower capsule size
• Reduced food effect
• More consistent exposure
• Improved swallowability
• Lower pill burden
• Combination therapy

A modified-release product would likely require a 505(b)(2) or abbreviated pathway analysis depending on the development strategy and reference product. The commercial value depends on clinical differentiation, payer coverage, and the ability to avoid direct price competition with standard carvedilol tablets.

4. Fixed-dose combinations

Carvedilol could be evaluated in combinations with agents used in cardiovascular disease, including diuretics, renin-angiotensin system inhibitors, or other antihypertensive classes. The principal formulation problem is compatibility between release profiles. A fixed-dose product that combines immediate-release and modified-release components can require separate layers, bilayer tablets, multiparticulate capsules, or staged-release systems.

Potential barriers include dose flexibility, titration requirements, contraindications, and the clinical need to adjust carvedilol separately from the second active ingredient.

What patents protect COREG and COREG CR?

The strongest historical protection for COREG CR related to the extended-release formulation and delivery technology, not the basic carvedilol molecule. COREG immediate-release tablets lost meaningful market exclusivity earlier than COREG CR because conventional carvedilol tablets were easier to develop and evaluate.

Patent and exclusivity profile

Issue	COREG immediate-release tablets	COREG CR extended-release capsules
Active ingredient protection	Expired	Expired or not commercially controlling
Formulation complexity	Low	Moderate to high
Current generic competition	Established	More limited than immediate-release tablets
Main IP risk	Product-specific patents and labeling	Release-control, formulation, and method-of-use patents
Regulatory route	ANDA	ANDA or other abbreviated pathway, depending on reference and claims
Commercial moat	Low	Manufacturing and regulatory execution

The Orange Book should be used to confirm currently listed patents, delisting events, pediatric exclusivity, and any remaining regulatory exclusivity for the relevant NDA. The FDA Orange Book identifies approved products, patent listings, and exclusivity information, but it does not establish whether every formulation or process patent is enforceable against a particular commercial product. [3]

When did COREG lose exclusivity?

COREG immediate-release tablets have been subject to generic competition for many years. The core carvedilol composition is no longer a meaningful market barrier. Commercial exposure is concentrated in price, supply reliability, channel access, and manufacturing scale.

COREG CR retained a more differentiated position because extended-release carvedilol requires a more complex formulation and bioequivalence package. Its remaining commercial protection depends on the specific patent listings and regulatory status attached to the relevant extended-release product. A current Orange Book review is required for transaction-grade expiration and Paragraph IV analysis.

Are there Paragraph IV challenges to COREG?

Paragraph IV risk is primarily relevant to listed formulation, method-of-use, or delivery patents associated with COREG CR. Immediate-release carvedilol has long been exposed to generic competition, so the relevant litigation question is not whether carvedilol can be copied generally. It is whether a proposed generic can enter with a formulation and labeling strategy that avoids any enforceable listed claims.

An ANDA applicant may:

• Certify that a listed patent has expired
• File a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed
• Use a section viii statement to omit a patented method of use
• Wait for patent expiration
• Challenge only selected claims while preserving other commercial options

A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act. A first applicant may receive 180-day generic exclusivity if statutory requirements are met, although the commercial value depends on the number of competing applicants and the patent outcome. [4]

What patent litigation affects COREG?

Historical COREG litigation has centered on generic entry, patent validity, infringement, and the scope of formulation or use claims. For current commercial analysis, litigation should be separated into three categories:

1. Litigation affecting immediate-release carvedilol tablets.
2. Litigation involving COREG CR extended-release capsules.
3. Litigation involving manufacturing processes or alternative release-control systems.

The practical risk is higher for a product that depends on a narrow extended-release architecture. A generic that uses a materially different polymer system may reduce literal infringement risk but still face development and regulatory hurdles.

What is the FDA regulatory status of COREG?

COREG and COREG CR are FDA-approved prescription products. The immediate-release tablet is an established oral dosage form with extensive generic precedent. COREG CR is a more complex extended-release product requiring tighter control of dissolution and exposure.

FDA approval does not give the branded product permanent market exclusivity. Regulatory protection is divided among:

• New chemical entity exclusivity
• Pediatric exclusivity
• Orphan exclusivity, if applicable
• Listed patents
• Data and market exclusivity
• Product-specific formulation protection

FDA labeling identifies the approved indications, strengths, dosage forms, excipients, warnings, and administration requirements. [1,2]

How does COREG compare with competing beta blockers?

Product	Active ingredient	Release profile	Excipient opportunity	Competitive position
COREG	Carvedilol	Immediate release	High for cost optimization	Mature generic market
COREG CR	Carvedilol phosphate	Extended release	High for coating and multiparticulate technology	More technically differentiated
TOPROL-XL	Metoprolol succinate	Extended release	Matrix or controlled-release platform	Large established generic market
Bystolic	Nebivolol	Immediate release	Conventional tablet optimization	Differentiated pharmacology
Lopressor	Metoprolol tartrate	Immediate release	Conventional tablet optimization	Mature generic market

COREG’s principal technical advantage is carvedilol’s combined beta- and alpha-1 blockade. Its commercial weakness is that immediate-release carvedilol is readily substitutable and highly price competitive.

What generic launch risks exist?

A generic COREG tablet faces low formulation risk but high commercial competition. A generic COREG CR product faces higher technical and regulatory risk, including:

• Dissolution mismatch
• Food-effect differences
• Inadequate release reproducibility
• Capsule-fill variation
• Polymer-coating scale-up failures
• Manufacturing-site transfer risk
• Patent litigation
• Limited reimbursement differentiation

The most attractive launch strategy is usually a reliable, low-cost immediate-release product supported by multiple API and excipient suppliers. The higher-margin strategy is a differentiated extended-release or adherence-oriented product, but that requires stronger clinical, regulatory, and manufacturing execution.

What manufacturing and IP barriers affect carvedilol products?

The immediate-release tablet has limited IP barriers. Manufacturing barriers are operational:

• Blend uniformity at low dose
• Powder flow
• Lubrication control
• Coating consistency
• Tablet identification
• Stability under heat and humidity

COREG CR has stronger process barriers:

• Uniform drug layering
• Tight particle-size control
• Reproducible membrane coating
• Controlled permeability
• Robust capsule filling
• Consistent dissolution across batches

These barriers can support contract manufacturing opportunities even when composition-of-matter patents have expired. Process capability, validated equipment, and regulatory history can be more valuable than ownership of a single excipient patent.

What licensing opportunities exist around COREG formulations?

Potential licensing targets include:

• Multiparticulate extended-release technology
• Ethylcellulose coating systems
• Co-processed direct-compression excipients
• Taste-masked or swallowability-enhanced oral solids
• Fixed-dose cardiovascular combinations
• Regional manufacturing rights
• Formulation technology transfer to emerging-market manufacturers

The strongest licensing case involves a product that reduces dosing frequency, improves stability, or supports a clinically meaningful combination. A simple excipient substitution in an immediate-release tablet is more likely to compete on price than command a royalty-bearing license.

Key Takeaways

• COREG is carvedilol immediate-release tablets; COREG CR is an extended-release carvedilol phosphate capsule.
• COREG tablets use conventional excipients and have low formulation complexity.
• The main immediate-release opportunities are generic cost reduction, supply security, and manufacturing efficiency.
• COREG CR has greater commercial value for multiparticulate coating, polymer science, and contract development.
• Carvedilol’s basic active-ingredient protection is no longer the principal barrier to entry.
• Current patent exposure should be assessed through the FDA Orange Book and relevant court records, especially for COREG CR.
• Paragraph IV risk is more commercially relevant to extended-release formulations than to mature immediate-release carvedilol.
• Excipient suppliers with direct-compression, film-coating, and ethylcellulose multiparticulate capabilities are best positioned to capture value.
• The strongest lifecycle opportunities are once-daily products, fixed-dose combinations, and formulations with measurable adherence or manufacturing advantages.

FAQs

Is carvedilol lactose-free?

The COREG tablet formulation identified by FDA labeling contains lactose monohydrate. Generic carvedilol products may use different fillers, so lactose content must be assessed product by product. [1]

Can a generic COREG tablet use different excipients?

Yes. A generic applicant can use a different excipient composition if the product meets FDA quality, performance, labeling, and bioequivalence requirements.

Does COREG CR use an osmotic pump?

No. COREG CR is described as a multiparticulate extended-release capsule using drug-containing particles and polymer-based release control rather than an osmotic tablet pump. [2]

Which excipient is most important for COREG CR release?

Ethylcellulose is a central release-controlling polymer in the labeled multiparticulate system. Coating thickness, plasticizer distribution, particle size, and processing conditions also determine release performance.

Is a carvedilol fixed-dose combination commercially attractive?

It can be attractive if it reduces pill burden or improves adherence, but carvedilol’s dose-titration requirements and cardiovascular contraindications complicate development, labeling, reimbursement, and market adoption.

References

1. U.S. Food and Drug Administration. (2023). COREG (carvedilol) tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2023). COREG CR (carvedilol phosphate) extended-release capsules: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards.